Lexpert Ranked Lawyer Profile
 
 
 

John E. Emanoilidis
Partner

Torys LLP

John E. Emanoilidis, Torys LLP

Co-head of Torys’ M&A Practice. Practice focuses on corporate/commercial and securities law, with an emphasis on M&A and corporate finance. Has significant experience in a wide range of corporate and securities law transactions, including complex M&A and corporate finance transactions. Also advises companies, directors and shareholders on corporate governance and securities compliance matters. Significant experience advising domestic and foreign acquirors, selling shareholders and investment banks in all aspects of M&A (public and private), including hostile take-over bids, strategic review processes, proxy contests, going-private transactions, private equity transactions and negotiated acquisitions. Extensive experience in corporate finance transactions, representing issuers, underwriters and investors in domestic and international debt and equity public offerings and private placements. Also provides ongoing advice to public companies on their disclosure, corporate governance and other corporate and securities law obligations. Editor-in-Chief of the Canadian Institute's Corporate Financing Journal and Merger and Acquisitions Journal. Ontario Bar, 1999. LLB, 1997, Osgoode Hall. BA (With High Distinction), 1994, University of Toronto.


Year Called to the Bar:1999 (ON)
79 Wellington St W, Suite 3000, Box 270, TD Ctr
Toronto, ON
Phone: (416) 865-8145
Fax: (416) 865-7380
E-mail: jemanoilidis@torys.com

Read more about John E. Emanoilidis in...

Big Deals, Suits or Real Estate Transactions

Mentioned in Lexpert Publications

  • Apr 27, 2018
    Special purpose acquisition corporations, or SPACs, have evolved in Canada, as legal advisors experiment with creative uses for the investment vehicle
  • Apr 27, 2018
    AI isn’t coming to law. It’s already here — and in a big way — as law firms augment their corporate legal services to exploit heretofore unheard-of efficiencies
  • Nov 24, 2017
    With amendments rendering the ‘poison pill’ effectively inert, private placements have become the de facto M&A defensive tactic. But there are limits to their usefulness.
  • Mar 21, 2017
    Fixed-fee long-form fairness opinion and report from independent transaction committee must be “minimum standard” in plans of arrangement, says judge
  • Aug 02, 2016
    The recent refusal of Canadian securities commissions to cease-trade a private placement may indicate that regulators’ approach to defensive tactics under the country’s new hostile takeover bid ...
  • Feb 10, 2016
    Its shares riding high, Concordia Healthcare was ready to snag UK-based pharma-corp Amdipharm Mercury last September. Then, two weeks after announcement, the deal faced headwinds as The New York ...
  • Oct 14, 2015
    When COS adopted a second poison pill that would require Suncor to double its 60-day minimum bid period or seek an order terminating the pill, it brought into focus the Canadian Securities ...